Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action

Chesnut, Charles H.; Ivey, Joel L.; Gruber, Helen E.; Matthews, Meredith; Nelp, Wil B.; Sisom, Karen; Baylink, David J.

doi:10.1016/0026-0495(83)90027-6

Cited by 158 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Androgenic side-effects are comparatively rare. Nevertheless, in the trial included here, 161 22% of patients receiving stanozolol (and none in the control group) complained of hoarseness, while 30% complained of increased facial hair compared with 9% in the control group. Virilisation is the side-effect most commonly encountered in women treated with nandrolone decanoate, with reported mean incidences of vocal changes in up to 38% of patients and hirsutism in 24%.…”

Section: Side-effectsmentioning

confidence: 77%

“…161 The agent used was stanozolol. Studies comparing anabolic steroids with other active interventions are discussed later (page 36).…”

Section: Anabolic Steroidsmentioning

confidence: 99%

“…161 No information was available relating to compliance in terms of both the number of patients who continued to take the medication and the proportion of medication that they had taken.…”

Section: Continuancementioning

confidence: 99%

See 2 more Smart Citations

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme continues to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider...

show abstract

Section: Side-effectsmentioning

confidence: 77%

“…161 The agent used was stanozolol. Studies comparing anabolic steroids with other active interventions are discussed later (page 36).…”

Section: Anabolic Steroidsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

show abstract

“…Several studies using synthetic androgens have suggested a positive effect of androgens on renal calcium handling. Therapy with the anabolic steroid, stanozolol, for 8 to 32 months in 23 women with postmenopausal osteoporosis decreased urinary calcium excretion by 32% (97). In addition, treatment with nandrolone decanoate for 3 months significantly increased renal tubular calcium reabsorption in 27 women with postmenopausal osteoporosis (92).…”

Section: Extraskeletal Effects Of Androgens On Calcium Metabolismmentioning

confidence: 99%

Androgen effects on bone metabolism: recent progress and controversies

Hofbauer

Khosla

1999

European Journal of Endocrinology

122

View full text Add to dashboard Cite

Androgens have beneficial effects on skeletal development and maintenance in women and men. The detection and functional characterization of androgen receptors in bone cells has implicated bone tissue as a potential target tissue for androgens. Gonadal and adrenal androgens directly regulate various aspects of osteoblastic lineage cells, including proliferation, differentiation, mineralization, and gene expression. These effects may differ depending on the stage of differentiation, the number of androgen receptors, and other inherent characteristics (species, site, cell biology) of the osteoblastic cell system. In addition, recent studies have suggested that some of the anabolic and anti-resorptive effects of androgens on bone may be mediated by regulation of autocrine and paracrine factors in the bone microenvironment, including transforming growth factor-b, insulin-like growth factors (and their binding proteins), and interleukin-6. This review summarizes the recent progress made in our knowledge of androgen receptor action, local androgen metabolism in bone, and direct and indirect effects of gonadal and adrenal androgens as well as androgen receptor antagonists on bone cells.

show abstract

“…Stanozolol, (17α-methyl-5α-androstano-[3,2-c]-pyrazol-17β-ol) ( Figure 1) was initially synthesized in 1959 [4] and clinically used in cases of deficiency in protein synthesis and osteoporosis [5]. Stanozolol, commonly sold under the name Winstrol (oral) and Winstrol Depot (intramuscular) and often called Winny was commercially developed by Winthrop Laboratories (Sterling Drug) in 1962, and has been approved for human use.…”

Section: Generic Namementioning

confidence: 99%

Urine Fingerprints of Stanozolol Treated Horses by Liquid Chromatography High Resolution Mass Spectrometry

Stojiljkovic¹,

Bubanj²,

Đorđević³

et al. 2017

J Sports Med Dop Stud

View full text Add to dashboard Cite

The current detection methods for stanozolol are all based on targeted approach. The present study aimed to assess the global biological effect of stanozolol-treatment by means of chemometric models, after generating and comparing horse urine LC-HRMS fingerprints collected from control and stanozolol-treated horses. The animal study was conducted according to an ethically approved protocol at two different places in France: Chamberet and Coye la Forêt. The total duration of the animal phase was seven months and only females were selected to partake. The sixteen mares in this study were not actively racing horses, but were in good physical condition. SIMCA-P+ software and R free software environment were used for multivariate data analysis. Principal Component Analysis (PCA) and Orthogonal Projections to Latent Structures-Discriminant Analysis (OPLS-DA) were applied to build some descriptive and predictive models. The analyzed horse urine fingerprints based on the 220 features selected after suppression of confounding factors show changes in metabolic states after chronic stanozolol treatment. This proof of concept study confirms the power of untargeted approach in doping control since the changes are present over seven months after anabolic administration.

show abstract

Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action

Cited by 158 publications

References 21 publications

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Androgen effects on bone metabolism: recent progress and controversies

Urine Fingerprints of Stanozolol Treated Horses by Liquid Chromatography High Resolution Mass Spectrometry

Contact Info

Product

Resources

About